Cell Therapies and Immunotherapy Conference

October 20-22, 2019
Add to Calendar

This conference will address challenges and discoveries in the cell therapy and immunotherapy fields that will ultimately change the future of healthcare.

Abstract Deadline: Sunday, September 1, 2019

Submit your Abstract

Register Here Today!

Invited Speakers:

  • Yvonne Chen, University of California, Los Angeles
  • Mohamad Hamieh, Memorial Sloan Kettering Cancer Center
  • Sadik Kassim, Kite Pharmaceuticals
  • David Miklos, Stanford University
  • Lior Nissim, The Hebrew University of Jerusalem
  • Shiladitya Sengupta, Massachusetts Institute of Technology
  • Pamela Skinner, University of Minnesota
  • Lili Yang, University of California, Los Angeles

Session Topics:

  • Update From the Frontline: CARs in the Clinic - Disease specific differences in outcomes and safety, real-world experience with CD28 vs. 4-1BB, solid vs heme
  • Mechanisms of Relapse and Strategies to Overcome - Antigen escape, tumor heterogeneity, T cell quality and persistence
  • Beyond Conventional CARs - Alternative CAR architectures, split CARs, TCRs, combination therapies
  • Gene Editing in Cell Therapy - Applications of editing, novel technologies, regulatory considerations for gene edited products
  • Moving Beyond Autologous T cells: Allogeneic and Other Cell Types - Allogeneic approaches, gd T cells, NK cells, iPSC derived products
  • Solid tumors: Increasing Specificity and Overcoming TME - Strategies to enhance tumor specificity, increase T cell trafficking, persistence, and potency
  • Bigger, Stronger, Faster: Synthetic Biology Approaches to Develop more Potent Therapies - Building synthetic gene circuits, delivering therapeutic payloads, armored CARs
  • Cell Therapy Applications Beyond Oncology - Using cells as therapeutics in autoimmune disease, CAR Tregs, etc.

Conference Chairs:

  • Amy Gilbert, Kite Pharma
  • Levi Rupp, Janssen, Inc.
  • Velia Siciliano, Italian Institute of Technology 

Organizing Committee:

  • Yvonne Chen, University of California, Los Angeles
  • Justin Eyquem, University of California, San Francisco
  • Lior Nissim, The Hebrew University-Hadassah Medical School
  • Barbra Sasu, Allogene Therapeutics
  • Navin Varadarajan, University of Houston 
  • Pin Wang, University of Southern California

Featured Speakers

Yvonne Chen

Yvonne earned her B.S. in Chemical Engineering from Stanford University and her Ph.D. in Chemical Engineering from the California Institute of Technology. She received postdoctoral training at the Center for Childhood Cancer Research within the Seattle Children's Research Institute, and at the Department of Systems Biology at Harvard Medical School. Yvonne was a Junior Fellow in the Harvard Society of Fellows prior to joining the Department of Chemical and Biomolecular Engineering at the University of California, Los Angeles in 2013. Dr. Chen has been a recipient of the NIH Director's...Read more

Mohamad Hamieh

Dr. Hamieh received his Ph.D. from Rouen University in France. Currently, he is a research associate in Dr. Michel Sadelain lab at Memorial Sloan Kettering Cancer Center in New York. His work focuses on understanding the dynamics of CAR T cell anti-tumor response. Recently, he described a new mechanism of antigen escape from CAR T cell therapy where T cells reduce target antigen density on tumor cells and T-cell activity via trogocytosis.Read more

David Miklos

Dr. Miklos is the Clinical Director of Stanford University’s Center for Cancer Cell Therapy, and leads Stanford’s CAR therapy clinical trials for patients with aggressive lymphomas.

David is a seasoned hematopoietic cell transplant (HCT) clinician and immunologist with special interest in B cell biology, tumor immunology and graft versus host disease (GVHD). His Stanford laboratory has applied cutting edge technologies to human translational research including:  protein microarrays for antibody identification, antigen specific B cell identification, and next-generation deep...Read more

Lior Nissim

Dr. Lior Nissim is an Assistant Professor leading the synthetic biology group in the Hebrew University of Jerusalem School of Medicine. His lab develop synthetic biology platforms implemented as effective, practical solutions for therapeutics and to decipher human biology.

Lior received his B.Sc. at the Tel-Aviv University. His M.Sc.  comprised of basic cancer biology research in the lab of Prof. Varda Rotter, Department of Molecular Cell Biology, Weizmann Institute of Science. He then accomplished his Ph.D the multidisciplinary biophysics lab of Prof. Roy Bar-Ziv , Department...Read more

Pamela Skinner

Dr. Skinner is a Professor in the Department of Veterinary and Biomedical Sciences at the University of Minnesota. Dr. Skinner’s HIV research program focuses on understanding disease immunopathogenesis and the development of novel immunotherapy treatments for HIV. Her HIV cure efforts are based on findings that B cell follicles are somewhat of an immune privileged site where low levels of virus-specific CTL allow ongoing HIV replication. She is presently working to develop a cellular immunotherapy which targets HIV-specific chimeric antigen receptor (CAR) T cells to B cell follicles to...Read more